Franklin Covey Added to Focus List and 3 Stock Analyses Not to Miss

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) target has been lowered by Roth Capital following the company’s CPP-109 to treat cocaine addiction failed in a clinical trial. The firm continues to believe that the company’s other products possess greater potential than CPP-109, and it keeps its Buy rating on the stock.

Franklin Covey Co. (NYSE:FC) has been added to Roth Capital’s Focus List after it reported stronger Q4 results than predicted. The firm keeps its Buy rating but raised its target to $18.50 from $17 on the stock.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Weatherford International Ltd. (NYSE:WFT) is expected by Barclays to give a new detailed financial strategy on the conference call, and it recommends purchasing the shares on weakness. Shares have an Overweight rating and a $18 price target.

F5 Networks, Inc. (NASDAQ:FFIV) ¬†iRules and iApp are believed by¬†Pacific Crest to give the company’s products “unmatched programmability.” The firm recommends purchasing the shares after they fell 35 percent from peak levels.

Don’t Miss: Clovis Oncology: This Treatment is Out of Reach.